Brief: Dyadic Receives U.S. Patent For Manufacturing Seasonal And Pandemic Influenza Vaccines From Its Proprietary C1 Protein Production Platform
18/04/2023 13:33
April 18 (Reuters) - Dyadic International Inc DYAI.O :
* DYADIC RECEIVES U.S. PATENT FOR MANUFACTURING SEASONAL AND
PANDEMIC INFLUENZA VACCINES FROM ITS PROPRIETARY C1 PROTEIN
PRODUCTION PLATFORM
Source text for Eikon: ID:nGNX3YcZ8T
Further company coverage: DYAI.O
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development